Leukemia, Acute Lymphocytic Clinical Trial
Official title:
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia
| Verified date | December 2023 |
| Source | Duke University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study will provide an evaluation of biologic markers of leukemia cell response following a single dose of copanlisib prior to any salvage induction therapy in a projected cohort of 10 relapsed/refractory B-ALL patients.
| Status | Terminated |
| Enrollment | 3 |
| Est. completion date | April 26, 2023 |
| Est. primary completion date | April 3, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Relapsed/refractory, Philadelphia chromosome positive or negative, B-cell, adult (= age 18) acute lymphoblastic leukemia (including bone marrow, extramedullary, CNS disease, or all), with or without prior hematopoietic stem cell transplant. Philadelphia chromosome positive patients prior to enrollment must have documented treatment failure to all FDA-approved for use in R/R ALL tyrosine kinase inhibitor (TKI) therapy, or have previously been deemed by their treating physician to not be a candidate for further TKI therapy. 2. ECOG 0-3. 3. CrCl = 30 mL/minute. 4. Bilirubin = 1.5x upper limit of normal (ULN), AST/ALT = 3x ULN. 5. Any patients with known pulmonary disease (including COPD, asthma, ongoing tobacco use, pulmonary hypertension, pulmonary sarcoidosis, or other relevant pulmonary disease which severely limits their pulmonary function), require an assessment of lung capacity with pulmonary function testing prior to acceptance to the study, with a threshold acceptance of DLCO > 40% corrected. Exclusion Criteria: 1. History of or concurrent condition of interstitial lung disease or autoimmune pneumonitis. 2. Active pneumonia requiring treatment, including Pneumocystis jirovecci pneumonia (PJP). 3. History of type 1 diabetes mellitus. 4. Type 2 diabetes mellitus with HgbA1C =10% while on treatment for diabetes. 5. Uncontrolled hypertension despite optimal medical management (per investigator's assessment). 6. Untreated human immunodeficiency virus (HIV). 7. Active replication of hepatitis B or active hepatitis C. Those with prior disease who are PCR negative at enrollment and meet liver function eligibility criterion are eligible. 8. Cytomegalovirus (CMV) infection with positive PCR at baseline. CMV PCR test is considered positive if the result can be interpreted as a CMV viremia according to institutional standard. 9. History of hematopoietic stem cell transplant with active GVHD requiring > 10 mg of prednisone daily or equivalent. 10. History of calcineurin inhibitor use in the last 28 days prior to enrollment. 11. Patients requiring immediate cytoreductive therapy. Exceptions for: patients whose peripheral blast counts are being controlled by single agent or combination therapy with steroids and/or hydroxyurea. 12. Pregnancy. 13. Active concurrent malignancy requiring ongoing treatment. Exceptions for: resected breast cancer being treated with hormonal therapy only, prostate cancer treated with hormonal therapy not progressing within the past year, if subject has received definitive local therapy (i.e., surgical excision, external beam radiation, or other local therapy with curative intent), non-melanoma skin cancers, or carcinoma in situ. 14. Active COVID-19 infection. 15. Progressive and/or uncontrolled infections despite active treatment. 16. Patients with residual toxicities related to prior treatment (including chemotherapy, immunotherapy, clinical trial, surgery, radiotherapy, or hematopoietic stem cell transplant) persistently > Grade 1 despite adequate treatment. Exceptions for: patients with residual toxicity related to prior treatment of =Grade 2 which is stable prior to enrollment and for which the natural history would not be expected to change over time; toxicity which cannot be reasonably excluded to be due to disease. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Duke Cancer Center | Durham | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Dorothy Sipkins, MD, PhD | Bayer |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Evaluate the effect of copanlisib exposure on alpha-6 integrin expression levels in leukemic blasts using flow cytometry. | 1 year | ||
| Secondary | Evaluate the effect of copanlisib exposure on proliferation of ALL blasts as determined by flow cytometric blast cell Ki-67 index. | 1 year | ||
| Secondary | Evaluate the effect of copanlisib exposure on proliferation of ALL blasts as determined by peripheral blood hematologic parameters (CBC and WBC differential including blast percentage). | 1 year |